Clinical Trial Website Update, page-28

One reason, from the recent quarterly . . . After all patients complete their dosing protocol of the Phase 1b part of the study, thedata will be analysed, a recommended Phase 2 dose chosen; we will report resultsto the market.

Besides, the safety and dosage aren't as interesting a reveal as they used to be.  They already pretty much said that it's safe and all patients had an immune response.  Again from the quarterly . . .  Study sites have reported no safety, toxicity or tolerability issues intreated patients. All vaccinated patients have developed immune responses andantibodies to HER2.

The stuff that hasn't been mentioned at all is the really interesting data, the efficacy and long term info.  This is what people really care about and are the sort of results that can make a splash. 

At 09:10 on 16 December at the ESMO conference, J. Tabernero will be giving a 20 minute talk on immune therapeutics in gastric and colorectal cancer.  With any luck the 1B results will be good enough to make an appearance.

Note - some nasty side-effect in a long term patient could derail things in a hurry.  Seems unlikely, but must be considered a possibility.  

Cheers.